Ovid Therapeutics Inc.

NasdaqCM:OVID Stock Report

Market Cap: US$451.7m

Ovid Therapeutics Valuation

Is OVID undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of OVID when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: OVID ($2.28) is trading below our estimate of future cash flow value ($15.85)

Significantly Below Future Cash Flow Value: OVID is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OVID?

Key metric: As OVID barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for OVID. This is calculated by dividing OVID's market cap by their current book value.
What is OVID's PB Ratio?
PB Ratio2.1x
BookUS$198.27m
Market CapUS$451.67m

Price to Book Ratio vs Peers

How does OVID's PB Ratio compare to its peers?

The above table shows the PB ratio for OVID vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average4.1x
PRLD Prelude Therapeutics
6.5x55.98%US$390.8m
VSTM Verastem
4x51.25%US$335.7m
AUTL Autolus Therapeutics
3.6x45.81%US$388.6m
XFOR X4 Pharmaceuticals
2.1x50.25%US$363.1m
OVID Ovid Therapeutics
2.1x-10.72%US$451.7m

Price-To-Book vs Peers: OVID is good value based on its Price-To-Book Ratio (2.1x) compared to the peer average (4.1x).

Historical Price to Book Ratio

Historical Price to Book Ratio compares a stock's price to the book value of it's equity over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Book Ratio vs Industry

How does OVID's PB Ratio compare vs other companies in the US Biotechs Industry?

62 CompaniesPrice / BookEstimated GrowthMarket Cap
CNTN Canton Strategic Holdings
0.4xn/aUS$187.08m
ENLV Enlivex
0.08x-147.76%US$166.95m
ENGN enGene Therapeutics
0.4x8.76%US$111.87m
FRMM Forum Markets
0.5x127.69%US$77.22m
OVID 2.1xIndustry Avg. 2.4xNo. of Companies84PB0246810+
62 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: OVID is good value based on its Price-To-Book Ratio (2.1x) compared to the US Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is OVID's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OVID PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.1x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate OVID's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst OVID forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$2.28
US$5.47
+139.96%
21.16%US$7.00US$4.00n/a9
Jun ’27US$2.56
US$5.47
+113.72%
21.16%US$7.00US$4.00n/a9
May ’27US$2.79
US$5.25
+88.13%
19.57%US$7.00US$4.00n/a9
Apr ’27US$2.16
US$4.55
+110.60%
35.70%US$7.00US$2.00n/a10
Mar ’27US$1.63
US$4.05
+148.40%
35.24%US$7.00US$2.00n/a10
Feb ’27US$1.56
US$4.05
+159.55%
35.24%US$7.00US$2.00n/a10
Jan ’27US$1.63
US$4.05
+148.40%
35.24%US$7.00US$2.00n/a10
Dec ’26US$1.80
US$4.19
+132.57%
36.92%US$7.00US$2.00n/a8
Nov ’26US$1.39
US$4.01
+188.80%
42.58%US$7.00US$1.50n/a7
Oct ’26US$1.37
US$3.40
+148.18%
38.80%US$5.50US$1.50n/a5
Sep ’26US$1.28
US$3.40
+165.63%
38.80%US$5.50US$1.50n/a5
Aug ’26US$0.50
US$2.88
+475.00%
31.05%US$4.00US$1.50n/a4
Jul ’26US$0.32
US$3.10
+881.01%
29.57%US$4.00US$1.50n/a5
Jun ’26US$0.27
US$3.10
+1,038.87%
29.57%US$4.00US$1.50US$2.565
May ’26US$0.32
US$3.20
+915.23%
23.39%US$4.00US$2.00US$2.795
Apr ’26US$0.31
US$3.20
+933.26%
23.39%US$4.00US$2.00US$2.165
Mar ’26US$0.53
US$3.38
+538.36%
34.15%US$5.00US$1.30US$1.636
Feb ’26US$0.66
US$3.38
+410.00%
34.15%US$5.00US$1.30US$1.566
Jan ’26US$0.93
US$3.26
+249.15%
37.70%US$5.00US$1.30US$1.635
Dec ’25US$1.14
US$3.26
+185.96%
37.70%US$5.00US$1.30US$1.805
Nov ’25US$1.14
US$3.26
+185.96%
37.70%US$5.00US$1.30US$1.395
Oct ’25US$1.12
US$3.26
+191.07%
37.70%US$5.00US$1.30US$1.375
Sep ’25US$1.13
US$3.33
+194.56%
39.55%US$5.00US$1.30US$1.287
Aug ’25US$0.99
US$3.31
+234.81%
40.40%US$5.00US$1.20US$0.507
Jul ’25US$0.86
US$3.31
+284.40%
40.40%US$5.00US$1.20US$0.327
Jun ’25US$3.06
US$7.56
+147.14%
29.46%US$11.00US$3.50US$0.278
US$5.47
Fair Value
58.3% undervalued intrinsic discount
9
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/10 21:27
End of Day Share Price 2026/06/10 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ovid Therapeutics Inc. is covered by 16 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madison Wynne El-SaadiB. Riley Securities, Inc.
Kalpit PatelB. Riley Securities, Inc.
Thomas ShraderBTIG